ST-266

N/A

Report date: 2024/04/19 14:36:30

Base Information

Drug NameST-266
Drug Alias NameST-266
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionNAD-dependent deacetylase sirtuin 1 stimulantsProto-oncogene proteins c-akt modulatorsBone development modulators +[4] 
TargetsNAD-dependent deacetylase sirtuin 1Proto-oncogene proteins c-akt
Therapy Area/IndicationsPersistent corneal epithelial defectBurnsCytokine Release Syndrome +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNoveomeUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesNoveome Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsCytokine Release SyndromeEnterocolitis, Necrotizing
Inactive IndicationsPersistent corneal epithelial defectBurnsDiabetes Mellitus +[7] 

Other Information

ATC CodeN/A
Related LinksN/A